Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program

BACKGROUND: Lenalidomide, a novel immunomodulatory agent, is reported to modulate stem cell differentiation, and have direct antiproliferative activity as well as inhibit inflammation and hyperalgesia. On the basis of this varied pharmacological profile, lenalidomide is under investigation as a trea...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Gorlick, Richard, Kolb, E. Anders, Lock, Richard, Maris, John M., Carol, Hernan, Morton, Christopher L., Billups, Catherine A., Smith, Malcolm A., Houghton, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505747/
https://ncbi.nlm.nih.gov/pubmed/21360651
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.22877
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados